1308677-02-2

Basic information

• Product Name: 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluorooctanedioic acid (3,4-dimethylphenyl)amide hydroxyamide
• Synonyms: 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluorooctanedioic acid (3,4-dimethylphenyl)amide hydroxyamide
• CAS NO: 1308677-02-2
• Molecular Weight: 508.264
• Mol File: 1308677-02-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluorooctanedioic acid (3,4-dimethylphenyl)amide hydroxyamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluorooctanedioic acid (3,4-dimethylphenyl)amide hydroxyamide(1308677-02-2)
• EPA Substance Registry System: 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluorooctanedioic acid (3,4-dimethylphenyl)amide hydroxyamide(1308677-02-2)

Safety Data

• Hazardous Substances Data: 1308677-02-2(Hazardous Substances Data)

Upstream product

• 1967-93-7 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluorooctanedioyl dichloride 
• 678-45-5 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluorooctanedioic acid 
• 1355356-58-9 benzyl 7-chlorocarbonyl-2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoroheptanoate 

Relevant articles and documents

Perfluorinated hydroxamic acids are potent and selective inhibitors of HDAC-like enzymes from Pseudomonas aeruginosa

A series of perfluorinated SAHA (PFSAHA) was prepared and profiled against a panel of human and bacterial members of the Histone deacetylase (HDAC) family. Some of the active substances show nanomolar inhibitory activity and several hundred fold selectivity for the HDAC like enzyme PA3774 from P. aeruginosa. The extraordinary selectivity against human HDACs results from the distinct oligomeric state of PA3774 which consists of two head-to-head dimers. The binding pocket is defined by the surface of both opposite monomers confining the access of ligands to the active site. In addition, the aromatic cap group of PFSAHA undergoes an edge-to-face aromatic interaction with phenylalanine from the opposite monomer.

Histone deacetylase (HDAC) inhibiting compounds and method of making same

The invention relates to novel HDAC inhibitors and a method of making such HDAC inhibitors. The present invention provides novel HDAC inhibitors having a perfluorinated linker between the metal-binding group and the cap group.